BIRC5 and neoplasm: For in vivo therapy, the scFv(AM1)-P-BAP-guided polyplexes containing the Survivin-specific siRNA (siSurv) were injected intraperitoneally (i.p.)every third day for 17 days into PC3PSCA tumor-bearing mice (Figure 4A).